Article
Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Antiviral therapy - 1 Jan 2017
Arias Ana, Aguilera Antonio, Soriano Vicente, Benítez-Gutiérrez Laura, Lledó Gemma, Navarro Daniel, Treviño Ana, Otero Esteban, Peña José M, Cuervas-Mons Valentín, de Mendoza Carmen
Abstract excerpt
BACKGROUND: Cure rates above 90% have been reported in most Phase III clinical trials using distinct all-oral direct-acting antivirals (DAAs) in chronic hepatitis C patients. Preliminary results in real-world patients have confirmed this, although efficacy tends to be lower. METHODS: All consecutive chronic hepatitis C patients treated with all-oral DAA regimens at three hepatitis clinics in Spain were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.